EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, CTMX: Cytomx Thera

27 Feb 26 17:21
LAST:

5.370

CHANGE:
 0.11		OPEN:
5.340		HIGH:
5.440		ASK:
10.150		VOLUME:
2.86M
CHG(%):
2.01		PREV:
5.480		LOW:
5.285		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
27 Feb 265.3405.4405.2855.3702.88M
26 Feb 265.7305.7405.3205.4802.21M
25 Feb 265.4806.1005.4765.7803.18M
24 Feb 265.5605.7405.4405.4401.89M
23 Feb 265.4105.6605.4005.5801.85M
20 Feb 265.3405.5555.3305.4301.91M
19 Feb 265.3705.6105.2305.4701.75M
18 Feb 265.2705.4255.1905.4103.92M
17 Feb 265.2805.4055.0305.2703.24M
13 Feb 265.4505.6505.3005.3203.67M

PROFILE

Name:Cytomx Thera
About:CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
Sector:Healthcare
Industry:Biotechnology
Address:151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Website:https://www.cytomx.com
CUSIP:23284F105
CIK:0001501989
ISIN:US23284F1057
FIGI:BBG001J472L3
LEI:5493004VW2FW0QLL3345

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:13.87 
Forward P/E:-11.87 
PEG Ratio:-0.07 
Price to Sales:4.17 
Price to Book:6.61 
Profit Margin:0.34 
Operating Margin:-0.07 
Return on Assets:0.16 
Return on Equity:1.08 
EPS Ratio:0.31 
Revenue:141.1M 
EBITDA:26.76M 
Shares:169.44M 
Market Cap:909.87M 

TECHNICAL INDICATORS

MA5:5.533.0%
MA10:5.461.6%
MA20:5.563.5%
MA50:5.007.5%
MA100:4.3722.9%
MA200:3.3460.6%
STO9:12.05 
STO14:12.05 
RSI14:41.67
WPR14:-80.39 
MTM14:-0.33
ROC14:-0.06 
ATR:0.35 
Week High:6.1013.6%
Week Low:5.291.6%
Month High:6.3518.2%
Month Low:5.0360.6%
Year High:6.3518.2%
Year Low:0.401,242.5%
Volatility:64.74